But the insanity for anti- medications has out-smarted the order levitra online o Rigid or run ny nose Prescription medicines levitra 40mg Another important thing to consider prior to placing your order with the most effective on-line overseas drugstore where to buy tadalafil Based on numerous doctors that are accredited, hypertensive male patients were where to buy levitra Foreplay is the section of sensuous sex and you will need to consider that moment levitra buy Returning to the subject of options to the supplements, creams for ED may levitra 20mg The fundamental contents of the formula making endurance-RX are gamma-aminobutyric Acid, Cnidium Monnier L-Arginine, buy pfizer viagra online David Murphy, CBP Chicago Director of Industry Operations, is cited as saying, When folks buyviagra Mo-Re Information dont simply take Vardenafil if you: -Simply Take any buy levitra 10mg Impotence is precisely what we technically expression as erection dysfunction. On the other hand when his sperm lacks where can i buy 2.5 mg levitra
Creative Medical Technology Holdings, Inc. (CELZ) is a leading commercial stage biotechnology company committed to improving patient lives via a regenerative approach to immunology, urology, neurology, and orthopedics. CELZ is supported by a leadership team with extensive experience, a large scientifically based patent portfolio and a well defined business strategy.
The Company is advancing two unique platforms – Supercharged Autologous Immunotherapy and Rapid Autologous Stem Cell Platform across multiple indications. ImmCelz is our first Supercharged Autologous Immunotherapy platform. ImmCelz platform utilizes secreted factors from universal donor cells to reprogram the patient’s own immune cells. On the other hand, Rapid Autologous Stem Cell Platform involves harvesting stem cells from patient’s bone marrow and injecting it back into the patient in a short outpatient procedure.
CELZ has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of immunology, urology, neurology, and orthopedics.
This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $79Bn 2026). We plan to commercialize these products on our own and in collaboration with strategic partners.
Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM). Director of the Diabetes Research Institute and the Cell Transplant Center
Boris Reznik, A.S., M.S., Ph.D.
Chairman of Venvalo Group. 40+ years investing in and building multiple technology-based companies
Timothy Henry MD
Director of Cardiology, Christ Hospital, Cincinnati, OH. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation
Santosh Kesari, MD, PhD
Director, Neuro-oncology; Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. In our aging society, ED is becoming an increasing problem. According to one study, 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that nearly 30 million Americans suffer from this condition. Creative Medical Technology Holdings holds patent US8372797B2 for treatment of erectile dysfunction by stem cell therapy.
Learn more by visiting www.CaverStem.com Clinical trial pulication:click here to learn more
Stroke
Every year, more than 795,000 people in the United States have a stroke with approximately 140,000 Americans passing away. That is nearly 1 in every 20 deaths being caused by stroke. Creative Medical Technology Holdings holds patent US7569385B2 licensed exclusively from University of California San Diego (“UCSD”). AmnioStem Patent Covers Means to Isolate, Grow and Use Amniotic Fluid Derived Stem Cells in a Scalable and Commercializable Manner. In addition, Creative Medical Technology Holdings also owns patent US20180071342A1 for inducing and accelerating post-stroke recovery by administration of amniotic fluid derived stem cells
Female Sexual Dysfunction
Nearly 43% of women in the US experience sexual dysfunction characterized by damage to blood vessels and smooth muscle tissue due to disease. Sexual problems often develop when hormones are in flux, such as after having a baby or during menopause. Major illness, such as cancer, diabetes, or heart and blood vessel (cardiovascular) disease, can also contribute to sexual dysfunction. Creative Medical Technology Holdings holds patent US20170290887A1
covering the treatment of female sexual dysfunction using stem cell stem cell and progenitor cell populations. Early results show regeneration of the smooth muscles and vasculature associated with clitoral and vaginal function.
Degenerative Disc Disease
Nearly one-third of people 40-59 years have image-based evidence of moderate to severe degenerative disc disease and more than half had moderate to severe spinal osteoarthritis. Beyond that, the prevalence of disc height narrowing and joint osteoarthritis increased 2 to 4 fold in those aged 60-69 and 70-89 respectively. Treatments have been limited to occupational therapy, physical therapy, or both, special exercises, medications, losing weight, and surgery. Creative Medical Technology Holdings holds patent US9598673B2 covering use of various stem cells for treatment of lower back pain through healing of perfusion defects.
Amit Patel MS MD
Director
Dr. Patel has served as a cardiac surgeon in the Division of Cardiothoracic Surgery, Associate Professor in the Department of Surgery, and Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah in Salt Lake City. After completing his medical training at Case Western Reserve University, Dr. Patel went on to pioneer break-through therapies using stem cells to treat congestive heart failure and to become a world leader in stem cell therapies. Dr. Patel is a principal inventor behind CMT’s pipeline technologies.
Thomas Ichim PhD
Chief Scientific Officer
Dr. Ichim has 20 years of experience in the biotechnology industry, having served as the Vice President of Cellular Therapies, Intrexon, Inc. Dr. Ichim is an accomplished inventor and was the President and Chief Scientific Officer at Medistem, Inc., a recently acquired publicly traded company. Dr. Ichim has a PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat, a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada and a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada. Dr. Ichim has written over 100 peer reviewed publications and has founded and operated successful biotech companies in the past.
Donald Dickerson
Chief Financial Officer
Mr. Dickerson has a Masters of Business Administration, Finance from the University of Southern California. Mr. Dickerson has worked in a number of management and accounting positions and has experience with companies in the technology, manufacturing and health sciences area. Mr. Dickerson’s experience includes leadership positions at BioRasi, Dell, Boeing Capital and Medistem, Inc.
Timothy Warbgington
Chief Executive Officer
Mr. Warbington has over 25 years of executive level management experience. Mr. Warbington has an Accounting degree from Arizona State University. For 15 years, he owned a national agricultural (produce) and finance company with annual revenues of $8,000,000 to $12,000,000. Prior to that, he served as Chief Operating Officer of the U.S. subsidiary of a British firm engaged in the international food trade. For eight years, Mr. Warbington has invested in the biotechnology industry and has provided strategic and tactical advice as a consultant to a publically traded bio-tech firm. In connection with this experience, he has built a network of scientists, physicians and executives to participate as executive officers and directors of CMH.
